Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)
Johnson & Johnson recorded quarterly Total Non-Current Liabilities of $119.2 billion in Q1 2026, up 1.74% quarter-over-quarter from $117.2 billion in Q4 2025, and up 4.28% year-over-year from $114.3 billion in Q1 2025.
Johnson & Johnson's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $119.2 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 4.28% year-over-year to $119.2 billion; the TTM figure through Mar 2026 stood at $119.2 billion (up 4.28% YoY), while the FY2025 annual figure was $117.2 billion, up 9.11% from the prior year.
- Total Non-Current Liabilities came in at $119.2 billion for Q1 2026 at Johnson & Johnson, up from $117.2 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $124.0 billion in Q2 2023 to a low of $93.7 billion in Q4 2023.
- A 5-year average of $107.4 billion and a median of $107.2 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities rose 20.16% in 2023 and slipped 18.66% in 2024, its largest moves.
- Johnson & Johnson's Total Non-Current Liabilities stood at $100.0 billion in 2022, then decreased by 2.31% to $97.7 billion in 2023, then increased by 9.93% to $107.4 billion in 2024, then climbed by 9.11% to $117.2 billion in 2025, then climbed by 1.74% to $119.2 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $119.2 billion, $117.2 billion, and $103.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 31.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 119.22 Bn |
| Dec 28, 2025 | 117.18 Bn |
| Sep 28, 2025 | 103.61 Bn |
| Jun 29, 2025 | 104.65 Bn |
| Mar 30, 2025 | 114.33 Bn |
| Dec 29, 2024 | 107.40 Bn |
| Sep 29, 2024 | 106.91 Bn |
| Jun 30, 2024 | 108.30 Bn |
| Mar 31, 2024 | 100.83 Bn |
| Dec 31, 2023 | 97.69 Bn |
| Oct 1, 2023 | 93.66 Bn |
| Jul 2, 2023 | 114.14 Bn |
| Apr 2, 2023 | 123.96 Bn |
| Jan 1, 2023 | 109.45 Bn |
| Oct 2, 2022 | 100.00 Bn |
| Jul 3, 2022 | 100.83 Bn |
| Apr 3, 2022 | 103.16 Bn |
| Jan 2, 2022 | 107.46 Bn |
| Oct 3, 2021 | 108.34 Bn |
| Jul 4, 2021 | 106.27 Bn |
| Apr 4, 2021 | 106.12 Bn |
| Jan 3, 2021 | 110.98 Bn |
| Sep 27, 2020 | 105.58 Bn |
| Jun 28, 2020 | 94.61 Bn |
| Mar 29, 2020 | 82.78 Bn |
| Dec 29, 2019 | 96.54 Bn |
| Sep 29, 2019 | 95.67 Bn |
| Jun 30, 2019 | 92.77 Bn |
| Mar 31, 2019 | 90.62 Bn |
| Dec 30, 2018 | 92.81 Bn |
| Sep 30, 2018 | 82.54 Bn |
| Jul 1, 2018 | 83.20 Bn |
| Apr 1, 2018 | 84.49 Bn |
| Dec 31, 2017 | 96.54 Bn |
| Oct 1, 2017 | 72.58 Bn |
| Jul 2, 2017 | 70.77 Bn |
| Apr 2, 2017 | 65.05 Bn |
| Jan 1, 2017 | 61.25 Bn |
| Oct 2, 2016 | 58.19 Bn |
| Jul 3, 2016 | 57.28 Bn |
| Apr 3, 2016 | 53.84 Bn |
| Jan 3, 2016 | 52.02 Bn |
| Sep 27, 2015 | 52.41 Bn |
| Jun 28, 2015 | 51.93 Bn |
| Mar 29, 2015 | 52.11 Bn |
| Dec 28, 2014 | 52.57 Bn |
| Sep 28, 2014 | 47.75 Bn |
| Jun 29, 2014 | 49.78 Bn |
| Mar 30, 2014 | 49.48 Bn |
| Dec 29, 2013 | 50.78 Bn |
| Sep 29, 2013 | 48.23 Bn |
| Jun 30, 2013 | 46.09 Bn |
| Mar 31, 2013 | 46.48 Bn |
| Dec 30, 2012 | 47.97 Bn |
| Sep 30, 2012 | 45.98 Bn |
| Jul 1, 2012 | 45.83 Bn |
| Apr 1, 2012 | 44.29 Bn |
| Jan 1, 2012 | 45.93 Bn |
| Oct 2, 2011 | 42.82 Bn |
| Jul 3, 2011 | 42.76 Bn |
| Apr 3, 2011 | 41.29 Bn |
| Jan 2, 2011 | 39.76 Bn |
| Oct 3, 2010 | 34.73 Bn |
| Jul 4, 2010 | 33.09 Bn |
| Apr 4, 2010 | 34.48 Bn |
| Jan 3, 2010 | 38.15 Bn |
| Sep 27, 2009 | 36.12 Bn |
| Jun 28, 2009 | 36.92 Bn |